|
|
 |
|
Viewing report
|
|
|
|
The Cardiovascular Market Outlook to 2010
Business Insights, Oct 2005, Pages: 174
The range of conditions within cardiovascular disease is wide, although the basic etiology of cardiovascular disease is generally well understood the focus on treatment in cardiovascular disease is twofold: firstly lowering the risk associated with cardiovascular risk factors in order to prevent an acute cardiovascular event; and secondly delaying or preventing the onset of chronic cardiovascular disease. This report provides information on the prevalence and incidence of cardiovascular disease in the seven largest pharmaceutical markets in 2004, and provides forecast epidemiological data for major therapeutic indications over the period 2004 to 2010.
The Cardiovascular Market Outlook to 2010 is a new offering a fully comprehensive analysis of the current and future market for cardiovascular drugs across all major indications.
Specific insight on growth brands, recent key events and future market leaders is provided, with corresponding epidemiological analysis and forecasts of major products over the period 2005-2010.
Whilst the outlook for the cardiovascular market as a whole is robust, the increasing availability of effective generic medicines and overall few launches of innovative new drugs means that growth rates in established indications are currently low. With few new sources of revenues, many of the major players in the cardiovascular market face underperforming cardiovascular portfolios, and over the next five years the competitive positions of the major players in the cardiovascular area are forecast to change.
Through detailed brand-level analysis and forecasts, this report provides insight into which companies will uphold their competitive position over the period 2005-2010, and identifies the potential cardiovascular blockbusters of the future.
Key Findings of the Report
- The cardiovascular portfolios of BMS, Novartis and AstraZeneca are best positioned for high future revenue growth. while current market leaders Pfizer, Merck and Sanofi-Aventis are forecast to struggle to maintain their current market shares by 2010.
- Over the period 2005-2010, only the dyslipidemia market is forecast to decline in net sales. The forecast decline is due to the patent expiry of Lipitor in 2010 and the prospective generic competition for the cardiovascular market’s highest selling product.
- The continuing dominance of Plavix and Lovenox in the thrombosis market has effectively set a high barrier to entry for new products which have to date failed to compete effectively on both efficacy and safety. Newer products may hold the key to further segmenting the thrombosis market and providing much needed competition.
- Thrombosis and heart failure represent the most active areas for current drug development, with hypertension now having few unmet needs. Increasing focus on these traditionally less competitive therapeutic areas is forecast to become a major trend in the cardiovascular area in the period 2005-2010.
The answers to your questions
- What will be the major growth indications in the cardiovascular market over the period 2005-2010?
- Which companies were the winners and losers in the cardiovascular market in 2004?
- How have recent major launches from Pfizer, AstraZeneca, and Merck performed?
- Which products will be impacted by generic competitors over the period 2005-2010?
- Which pipeline products will be the growth drivers of the future and why?
- What will the competitive landscape in hypertension, thrombosis, dyslipidemia and arrhythmia look like in 2010?
Why you should order your copy today
- Save time and money in research with the report’s coverage of all the major indications in the cardiovascular area, the seven largest geographic pharmaceutical markets and 6 of the largest companies active in the cardiovascular area today.
- Quickly understand how recent events are affecting the performance of major products, and how leading pharmaceutical companies are confronting these challenges and preparing themselves for future growth in the cardiovascular marketplace.
- Gain up-to-date competitive intelligence across the cardiovascular area and understand the major issues affecting key pharmaceutical marketers.
- Understand which cardiovascular indications have the greatest potential to provide franchise growth, and how your competitors are attempting to exploit these opportunities.
- Compare the franchises of key players in the cardiovascular market across major indications, and understand how the market shares of leading companies will change over the next 5 years.
Customers who bought this item also bought
The Cardiovascular Disorders Market Outlook to 2012
The Cardiovascular Market Outlook to 2013: Competitive Landscape, Global Market Analysis and Pipeline Analysis
The Cardiovascular Market Outlook to 2011
The Cardiovascular Market Outlook to 2008
The Asian Cardiovascular Market Outlook to 2010
The Latin American Cardiovascular Market Outlook to 2010
The Eastern European Cardiovascular Market Outlook to 2010
The Asian Cardiovascular Market Outlook to 2014: Regional and Therapeutic Analysis, Pipeline Impact and Growth Opportunities
Cardiovascular Drug Discoveries 2008
The Cardiovascular Outlook to 2007
The Cardiovascular Market Outlook to 2009
Commercial Insight: Cardiovascular Market Overview - Raft of Patent Expires Threaten Blockbusters
|
|
|
|
